Come join C4T! We are recruiting for key roles on our team to help us advance our pipeline of targeted protein degrader programs. Take a look at our open roles: https://bit.ly/3pg4NTH At C4T, we work hard to identify and assemble the right talent to move our work forward, like Eunju Hurh, our vice president, head of clinical pharmacology. Read about her path to joining our team here: https://bit.ly/3qEOReg
C4 Therapeutics, Inc.
Biotechnology
Watertown, MA 14,788 followers
Clinical-stage biotech company transforming how disease is treated through targeted protein degradation science
About us
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes.
- Website
-
http://www.c4therapeutics.com
External link for C4 Therapeutics, Inc.
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Watertown, MA
- Type
- Public Company
- Founded
- 2016
- Specialties
- biotechnology, cell biology, protein chemistry, cell pharmacology, and Protein Degradation
Locations
-
Primary
490 Arsenal Way
Suite #120
Watertown, MA 02472, US
Employees at C4 Therapeutics, Inc.
Updates
-
C4 Therapeutics will present preliminary data from the ongoing Phase 1/2 study of CFT1946, our novel BiDAC™ degrader in mutant BRAF V600 solid tumors, at the ESMO - European Society for Medical Oncology Congress being held September 13-17 in Barcelona. Learn more: https://bit.ly/3WnpgUq #ESMO24
-
-
C4 Therapeutics will participate in a fireside chat at the UBS Targeted Protein Degradation Day occurring virtually on July 15. Learn more: https://bit.ly/4eRJpZU
-
-
As we advance degraders through clinical trials, it is crucial to have a seasoned regulatory strategy leader who understands the landscape of oncology drug development, approval and path to commercialization. At C4T that leader is Mary Christian, senior vice president, regulatory. Mary has over 20 years of industry experience, including regulatory approvals, managing strategic collaborations in oncology and overseeing the expansion of commercial asset indications. Learn more about Mary and our leadership team: https://bit.ly/3EQBafX
-
Cemsidomide, an orally bioavailable degrader, is currently being evaluated in a Phase 1/2 clinical trial as a potential treatment for multiple myeloma and non-Hodgkin's lymphoma. Learn more on our website: https://bit.ly/4bsj5TU #TPD
-
-
On Juneteenth, we recognize the continued urgency for true equality around the world and the importance of supporting black communities. To support black owned businesses in Boston, check out the Seaport X Black Owned Bos. market series: https://bit.ly/4501T66
-
-
In honor of #Pride and our commitment to bringing our unique selves to C4T, Nicole Follmer, a member of our DEI Council, led a discussion with Ashley Boyd, Leonard Reyno and Catherine Solovay, PMP about allyship. #PrideMonth
-
-
It’s that time of year! We’re excited to enter summer the C4T way - welcoming our 2024 intern class brought to us in partnership with Project Onramp. Our whole team looks forward to working with this motivated group of students eager to learn about career opportunities in life sciences. Our interns will work across multiple functions at C4T, contributing to the cell pharmacology, program management, regulatory and translational medicine teams. Welcome, Cristina Vasquez Genesis Castillo Kaitlyn Taliaferro Fua Nasu!
-
-
We’re excited to announce the appointment of Ron Cooper as chairman of our Board of Directors as C4T continues its evolution to become a fully integrated biotech. Ron brings decades of global pharmaceutical and biotech leadership across drug development, advancing treatments through discovery, development and commercialization. The C4T team is thrilled to have Ron’s experience as we advance our targeted protein degradation science for patients. Read more in our latest release: https://bit.ly/45lRJwO
-
Have you heard about Deggie? Our integrated laboratory automation machine is a tool that enables our #TPD science, allowing us to efficiently manage the wide array of biochemical and cellular assays needed to screen and characterize potential drug molecules. To us, Deggie symbolizes our science and the work we’ve done to create new, transformative medicines. Read Deggie’s story here: https://bit.ly/4apfeFR
-